356 related articles for article (PubMed ID: 17806124)
1. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
Andersson KE; Uckert S; Stief C; Hedlund P
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
[TBL] [Abstract][Full Text] [Related]
3. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
Werkström V; Svensson A; Andersson KE; Hedlund P
BJU Int; 2006 Aug; 98(2):414-23. PubMed ID: 16626307
[TBL] [Abstract][Full Text] [Related]
5. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract.
Christ GJ; Andersson KE
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):948-54. PubMed ID: 17696159
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Wang C
Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
[TBL] [Abstract][Full Text] [Related]
7. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Wong P; Lawrentschuk N; Bolton DM
Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
[TBL] [Abstract][Full Text] [Related]
9. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.
Uckert S; Hedlund P; Andersson KE; Truss MC; Jonas U; Stief CG
Eur Urol; 2006 Dec; 50(6):1194-207; discussion 1207. PubMed ID: 16815627
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Küthe A; Montorsi F; Andersson KE; Stief CG
Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer with phosphodiesterase inhibitors.
Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
[TBL] [Abstract][Full Text] [Related]
12. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
13. Lower urinary tract symptoms and sexual dysfunction: a common approach.
Giuliano F
BJU Int; 2008 Mar; 101 Suppl 3():22-6. PubMed ID: 18307682
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Giuliano F; Ückert S; Maggi M; Birder L; Kissel J; Viktrup L
Eur Urol; 2013 Mar; 63(3):506-16. PubMed ID: 23018163
[TBL] [Abstract][Full Text] [Related]
15. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate.
Uckert S; Küthe A; Jonas U; Stief CG
J Urol; 2001 Dec; 166(6):2484-90. PubMed ID: 11696815
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
Francis SH; Corbin JD
Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
[TBL] [Abstract][Full Text] [Related]
17. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
[TBL] [Abstract][Full Text] [Related]
18. Cyclic adenosine monophosphate and cyclic guanosine monophosphate-phosphodiesterase isoenzymes in human vagina: relation to nitric oxide synthase isoforms and vasoactive intestinal polypeptide-containing nerves.
Uckert S; Oelke M; Waldkirch E; Stief CG; Albrecht K; Tröger HD; Jonas U; Andersson KE; Hedlund P
Urology; 2005 Mar; 65(3):604-10. PubMed ID: 15780401
[TBL] [Abstract][Full Text] [Related]
19. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro.
Truss MC; Uckert S; Stief CG; Forssmann WG; Jonas U
Urol Res; 1996; 24(3):129-34. PubMed ID: 8839479
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.
Uckert S; Kuczyk MA
Handb Exp Pharmacol; 2011; (202):527-42. PubMed ID: 21290241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
